To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationI would now like to turn the conference over to Vivian Cervantes, CORE Investor Relations. Please go ahead.Good day, and welcome to the Plus Therapeutics January 22, 2026, Business Update Conference Call. [Operator Instructions] Please note that this event is being recorded.Vivian Cervantes Thank you, Chloe. Good morning, and thank you for participating in today's conference call. Earlier this morning, the company released a business update and outline of progress in its REYOBIQ clinical program ...

Plus Therapeutics (NasdaqCM:PSTV) Update / briefing January 22, 2026 09:00 AM ET Company ParticipantsAndrew Sims - CFOMarc Hedrick - CEOVivian Cervantes - Head of Investor RelationsConference Call ParticipantsJason Kolbert - AnalystEdward Woo - AnalystSean Lee - AnalystOperatorGood day and welcome to the Plus Therapeutics January 22nd, 2026, Business Update Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star ke ...

Corporate Update January 2026 Power and precision in cancer radiotherapeutics NASDAQ: PSTV Cautionary Note Regarding Forward Looking Statements This presentation contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forward-looking statements m ...

Core Insights - Plus Therapeutics, Inc. is advancing its clinical-stage pharmaceutical initiatives focused on targeted radiotherapeutics for central nervous system (CNS) cancers, with significant progress in both clinical trials and diagnostic platform technologies [2][8] Corporate Highlights - The company completed a restructuring of a $15 million equity financing, simplifying its capital structure [6] - Plus Therapeutics received an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a previously awarded $17.6 million grant [6] - The company appointed Kyle Guse, an industry veteran with 30 years of experience, to its Board of Directors [6] - Plus Therapeutics presented updated interim data on its lead compound REYOBIQ™ at a conference, highlighting its safety and clinical benefits for patients with leptomeningeal metastases [6] Clinical Development - The REYOBIQ™ clinical trials are demonstrating favorable safety and efficacy signals, which are facilitating active enrollment in the dose optimization trial [2][4] - The company initiated the ReSPECT-LM dose optimization trial for REYOBIQ, treating the first two patients to evaluate multiple-dose regimens [6] - The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for REYOBIQ for pediatric patients with specific high-grade gliomas, supported by a $3 million grant from the Department of Defense [6] CNSide CSF Assay Platform - The CNSide CSF assay platform is set to launch in Texas, focusing initially on National Cancer Institute Designated Cancer Centers [10] - The total addressable market for the CNSide CSF Tumor Cell Enumeration (TCE) test is estimated to be $6 billion in the U.S., with plans to add three additional CNS assays [10] - The company aims to expand CNSide testing services regionally over the next 12 months [2][10] Financial Performance - As of June 30, 2025, the company reported cash and investments of $6.9 million, an increase from $3.6 million at the end of 2024 [10] - Grant revenue for Q2 2025 was $1.4 million, compared to $1.3 million in the same quarter of 2024 [10] - The total operating loss for Q2 2025 was $1.5 million, a decrease from $3.7 million in Q2 2024, attributed to improved operational cost control [10] - The company reported a net income of $5.2 million for Q2 2025, a significant turnaround from a net loss of $2.9 million in the same quarter the previous year [10]

Market Overview - U.S. stocks showed mixed performance with the Dow Jones index falling approximately 0.2% to 43,011.70, while the NASDAQ rose by 0.20% to 19,953.27 and the S&P 500 increased by 0.02% to 6,093.14 [1] - Information technology shares experienced a notable increase of 0.8%, while real estate stocks declined by 1.3% [1] Commodities - Crude oil prices rose by 2.5% to $65.99, gold increased by 0.3% to $3,343.80, silver was up 1% to $36.070, and copper rose by 0.7% to $4.9605 [5] European Markets - European shares were generally lower, with the eurozone's STOXX 600 falling by 0.74%, Spain's IBEX 35 Index down 1.59%, London's FTSE 100 down 0.46%, Germany's DAX 40 down 0.61%, and France's CAC 40 slipping by 0.76% [6] Asian Markets - Asian markets closed higher, with Japan's Nikkei gaining 0.39%, Hong Kong's Hang Seng Index up 1.23%, China's Shanghai Composite rising 1.04%, and India's BSE Sensex increasing by 0.85% [7] Company News - Plus Therapeutics, Inc. saw its shares surge by 59% to $0.2968 following FDA clearance for its investigational new drug application for REYOBIQ [9] - QuantumScape Corporation's shares rose by 36% to $5.88 after achieving a key milestone in integrating its advanced Cobra separator process [9] - SeaStar Medical Holding Corporation's shares increased by 49% to $0.5362 due to strategic actions for Nasdaq compliance [9] - Lifeward Ltd. experienced a drop of 38% to $0.6015 after announcing a public offering of 4 million shares at $0.65 per share [9] - Torrid Holdings Inc. shares fell by 37% to $3.1900 following the pricing of a secondary offering of 10 million shares at $3.50 per share [9] - Allot Ltd. shares decreased by 17% to $8.01 after announcing a public offering of 5 million shares at $8.00 per share [9] Economic Indicators - Sales of new single-family homes in the U.S. decreased by 13.7% to an annualized rate of 623,000 units in May [11] - U.S. building permits fell by 2% to an annualized rate of 1.394 million in May [11] - The volume of mortgage applications in the U.S. increased by 1.1% from the previous week [11] - U.S. crude oil inventories declined by 5.836 million barrels, significantly exceeding market estimates of a 0.75 million barrel decrease [11]